Partnership
Build the next generation of therapeutics with us.
From co-discovery on novel targets to licensing of preclinical assets — we work with pharma and biotech across three engagement models.
Discovery collaborations
Co-development of novel therapeutic candidates against shared targets, leveraging our 2B+ compound library and DTIGN screening stack.
Asset licensing
Out-licensing of preclinical and IND-stage programs in metabolic health, inflammation, and oncology.
Platform access
Access to our AI screening and generative chemistry platform under a structured services arrangement.
Ready to start?
Our BD lead will respond within 2 business days with a mutual NDA.